Monte Rosa Therapeutics (NASDAQ:GLUE) versus Qiagen (NASDAQ:QGEN) Head-To-Head Comparison

Monte Rosa Therapeutics (NASDAQ:GLUE – Get Rating) and Qiagen (NASDAQ:QGEN – Get Rating) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations and risk.

Profitability

This table compares Monte Rosa Therapeutics and Qiagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	N/A	-42.09%	-33.94%
Qiagen	17.66%	14.08%	7.61%

Valuation & Earnings

This table compares Monte Rosa Therapeutics and Qiagen’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	N/A	N/A	-$108.50 million	($2.43)	-2.60
Qiagen	$2.14 billion	4.84	$423.21 million	$1.54	29.57

Qiagen has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and target prices for Monte Rosa Therapeutics and Qiagen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	0	1	3	0	2.75
Qiagen	0	0	0	0	N/A

Monte Rosa Therapeutics presently has a consensus price target of $17.75, indicating a potential upside of 181.30%. Given Monte Rosa Therapeutics’ higher probable upside, research analysts plainly believe Monte Rosa Therapeutics is more favorable than Qiagen.

Risk and Volatility

Monte Rosa Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Insider and Institutional Ownership

83.2% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 58.6% of Qiagen shares are owned by institutional investors. 5.3% of Monte Rosa Therapeutics shares are owned by insiders. Comparatively, 9.0% of Qiagen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Qiagen beats Monte Rosa Therapeutics on 8 of the 12 factors compared between the two stocks.

About Monte Rosa Therapeutics

(Get Rating)

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

About Qiagen

(Get Rating)

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.